YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

Isis and Biogen Sign Six Year Collaboration

September 9, 2013 | Isis Pharmaceuticals signed a six-year agreement with Biogen Idec to develop new therapies to treat neurological disorders. Isis is eligible to receive $100 million in milestone payments, license fees, and royalty payments. Bloomberg Businessweek
Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.